论文部分内容阅读
目的探讨大环内酯类抗菌药物在下呼吸道感染患者中的应用效果。方法选取2011年1月-2014年1月收治的下呼吸道感染患者146例,依据临床特点将患者分为低危人群与高危人群。低危人群治疗方案通常首选红霉素胶囊0.25 g/次、3次/d+复方甘草合剂,其次为克拉霉素0.25 g/次、2~3次/d+复方甘草合剂,或克拉霉素0.25 g/次、2~3次/d+复方甘草合剂;高危人群治疗方案为大环内酯类抗菌药物(红霉素、克拉霉素)0.25 g/次、3次/d+第2代头孢菌素类抗生素(头孢克洛或头孢呋辛)0.25 g/次、3次/d+复方甘草合剂口服。结果 146例患者7 d临床治愈率为54.1%,总有效率为93.1%;低危人群治疗下呼吸道感染7 d治愈率为63.6%,总有效率为94.9%;高危人群组治疗下呼吸道感染7 d治愈率为34.0%,总有效率为89.4%;急性支气管炎7 d临床治愈率高,达70.1%。结论大环内酯类抗菌药物(红霉素、克拉霉素)口服治疗下呼吸道感染疗效可靠,值得在临床推广应用。
Objective To investigate the effect of macrolide antibiotics in patients with lower respiratory tract infection. Methods One hundred and sixty-six patients with lower respiratory tract infection were selected from January 2011 to January 2014. Patients were divided into low-risk group and high-risk group according to clinical characteristics. Low-risk population treatment options usually preferred erythromycin capsules 0.25 g / times, 3 times / d + compound licorice mixture, followed by clarithromycin 0.25 g / times, 2 or 3 times / d + compound licorice mixture, or clarithromycin 0.25 g / Times, 2 to 3 times / d + compound licorice mixture; high-risk population treatment of macrolide antibiotics (erythromycin, clarithromycin) 0.25 g / times, 3 times / d + second generation cephalosporins Antibiotics (cefaclor or cefuroxime) 0.25 g / time, 3 times / d + compound licorice mixture oral. Results The cure rate of 146 cases was 54.1% on 7 days and the total effective rate was 93.1%. The cure rate of low-risk group was 63.6% on 7 days and the total effective rate was 94.9%. The treatment of lower respiratory tract infection 7 d cure rate was 34.0%, the total effective rate was 89.4%; 7 days acute bronchitis clinical cure rate was high, up to 70.1%. Conclusion The macrolide antibiotics (erythromycin, clarithromycin) oral treatment of lower respiratory tract infection is reliable and worthy of clinical application.